Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06873600 dose-escalation and expansion study in advanced solid tumors and HR-positive/HER2-negative metastatic breast cancer
2020-001757-40Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ebvaciclib in breast cancer, triple-negative breast cancer (TNBC), ovarian cancer and 2 more (3 arms), sponsored by Pfizer. Primary endpoint: Safety and tolerability. Started Aug 2021; status: completed.
02
Drugs
ebvaciclib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2020-001757-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001757-40.